Therapy with standard chemotherapy in TP53 mutated AML with loss of TP53 allele displays a lack of chemotherapy induced apoptosis and subsequently a poor response rate (RR), disease-free survival (DFS) and OS while being independent of cytogenetic aberration [5] Decitabine (DAC) has been shown to enhance chemotherapy response in patients harboring TP53 mutations, however, it has not been able to deliver a durable response or clear subclones of TP53 mutations [127,128]. Here, TP53 is linked to acute myeloid leukemia.